REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 201 filers reported holding REATA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.11 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $204 | +12.1% | 2 | 0.0% | 0.00% | – |
| Q1 2023 | $182 | +139.5% | 2 | 0.0% | 0.00% | – |
| Q4 2022 | $76 | – | 2 | 0.0% | 0.00% | – |
| Q3 2022 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q2 2022 | $0 | – | 2 | 0.0% | 0.00% | – |
| Q1 2022 | $0 | -100.0% | 2 | -99.7% | 0.00% | -100.0% |
| Q4 2021 | $16,000 | -74.2% | 618 | 0.0% | 0.01% | -76.9% |
| Q3 2021 | $62,000 | -28.7% | 618 | 0.0% | 0.03% | -3.7% |
| Q2 2021 | $87,000 | +33.8% | 618 | -4.5% | 0.03% | +42.1% |
| Q1 2021 | $65,000 | -18.8% | 647 | 0.0% | 0.02% | -20.8% |
| Q4 2020 | $80,000 | -34.4% | 647 | -48.5% | 0.02% | -41.5% |
| Q3 2020 | $122,000 | +6.1% | 1,256 | +71.1% | 0.04% | +2.5% |
| Q2 2020 | $115,000 | +8.5% | 734 | 0.0% | 0.04% | -7.0% |
| Q1 2020 | $106,000 | -48.5% | 734 | -27.1% | 0.04% | -29.5% |
| Q4 2019 | $206,000 | +216.9% | 1,007 | +24.8% | 0.06% | +190.5% |
| Q3 2019 | $65,000 | -14.5% | 807 | +0.2% | 0.02% | -16.0% |
| Q2 2019 | $76,000 | – | 805 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |